- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03986320
Évaluation de l'efficacité et de l'innocuité du dermosquelette Keeogo™ chez les sujets à mobilité réduite suite à un AVC
Un essai multisite, interventionnel, comparatif et à un seul bras pour évaluer l'innocuité et l'efficacité du dermosquelette Keeogo™ chez les sujets atteints d'hémiparésie due à un AVC ischémique ou hémorragique.
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Stroke affects thousands of individuals annually, leading to considerable physical impairment and functional disability. Gait is one of the most important activities of daily living affected in this patient population. Recent technological developments in passively powered dermoskeleton can create powerful adjunctive tools for rehabilitation and potentially accelerate functional recovery. Here, the investigators present the development and evaluation of a lower limb dermoskeleton, namely Keeogo™ (B-Temia), for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M6A 2E1
- Assistive Technology Clinic (ATC)
-
-
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Shirley Ryan Ability Lab (SRA)
-
-
New Jersey
-
West Orange, New Jersey, États-Unis, 07052
- Human Performance and Engineering Research (HPER)
-
-
New York
-
The Bronx, New York, États-Unis, 10468
- James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
To be eligible to participate in this study, an individual must meet all of the following criteria:
-
Provide signed and dated informed consent form;
-
Willing to comply with all study procedures and be available for the duration of the study [2-3 days per week, 3-5 consecutive weeks];
-
Adults 18 years of age and older;
-
Confirmed Cerebrovascular Accident (CVA) with hemiparesis;
-
Stable stroke (≥ 6 months post-incident)
-
Sufficient cognition to follow simple instructions and understand the content and purpose of the study (MMSE > 20);
-
Capable of standing and walking independently for an extended period of time (MMT
- 3 hip flexors and extensors, and ≥ 2 knee flexors and extensors with BBS ≥ 45);
-
Presence of any gait deficit, as defined by one or more of the following clinical observations:
- Hip hike
- Hip circumduction
- Knee spasticity (MAS 2 to 3) as per Modified Ashworth Scale (MAS)
- Mid-foot striking (aka 'flat foot landing')
- Poor foot clearance (toe/foot drop or foot drag)
- Narrow steps (< 1 shoe-width or < 8 cm)
-
Manual Muscle Test (MMT) of 4/5 for the unaffected upper extremity;
-
Able to sit on a bench for more than 5 minutes;
-
Is physically and mentally compatible with device to demonstrate ability to safely activate the Keeogo™ user interface;
-
Able to understand and follow instructions with assistance if needed.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Legally blind
- Pregnant, lactating, or postpartum sacroiliac joint recovery is ongoing (recent childbirth, not yet cleared for vigorous exercise)
- Skin condition that contraindicates use of orthotics or support braces
- Recent (<6 mo) lower-body hospitalizations or active treatments due to a joint, muscle, bone, nerve or vascular injury or condition
- Scheduled for major surgery within next 4 months
- Lower-extremity amputation above or below the knee
- Have uncontrolled hypertension
- Recent (<1 year) heart attack
- Have uncontrolled diabetes
- Diagnosed with other health condition(s) that affect mobility and balance; chronic obstructive pulmonary disease; peripheral arterial disease; vestibular disorders; cerebellar disease; cerebral palsy; muscular dystrophy spinal cord injury; other brain injury aside from the reported CVA;
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Keeogo™ Dermoskeleton
Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves. |
This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of device-related adverse events [Safety]
Délai: Duration of study participation for each subject, estimated 3-5 weeks
|
Safety will be evaluated on the basis of the number of device-related serious adverse events reported for subjects during their participation in the study. |
Duration of study participation for each subject, estimated 3-5 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of device malfunctions during study procedures [Device Reliability]
Délai: Duration of study completion for each site, estimated 3-5 weeks
|
Device reliability will be evaluated on the basis of the number of device malfunctions reported by research study staff for the duration of study procedures at each study site. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Incidence of injury to Physical Therapist (PT) caused by device [PT safety]
Délai: Duration of study completion for each site, estimated 3-5 weeks
|
PT safety will be evaluated on the basis of the number of serious device-related injuries reported by study physical therapists for the duration of study procedures at each study site. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Device, Effectiveness
Délai: Duration of study participation for each subject, estimated 3-5 weeks
|
Clinician and Patient Reported Outcomes (surveys) will be used to assess the effectiveness of the device in assisting gait. The surveys will rate subject performance in walking based on clinician observed deviations and subject perception of mobility limitation due to the stroke.
|
Duration of study participation for each subject, estimated 3-5 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
30-Second Chair Stand Test
Délai: Duration of study completion for each site, estimated 3-5 weeks
|
Subjects sit in the middle of chair and place hands on opposite shoulder crossed at wrists. Keeping feet flat on floor, back straight, arms against chest, subjects rise to full standing position when told "go" followed by sit down, the start position. This movement is repeated for as many times as possible for 30 seconds. Additionally, the test is repeated for a total of 5 cycles with short rest (≤ 90 seconds) between sets. Patient and Clinician reported outcomes are assessed for this measure via a sit-to-stand-to-sit question on the survey given for the secondary effectiveness endpoint. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Timed Stair Test
Délai: Duration of study completion for each site, estimated 3-5 weeks
|
Subjects start with both feet on the bottom landing then ascend and descend a set number of stairs as quickly as possible in a safe manner using a rail only if needed. Time is recorded from ascent through descent. Patient and Clinician reported outcomes are assessed for this measure via a stair ascent/descent question on the survey given for the secondary effectiveness endpoint. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Patient and Clinician Reported Outcomes (surveys)
Délai: Duration of study completion for each site, estimated 3-5 weeks
|
Questionnaires provide patient and clinician-centric view of treatment of gait deficit. |
Duration of study completion for each site, estimated 3-5 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Arun Jayaraman, PT, PhD., Shirley Ryan Ability Lab (SRA)
Publications et liens utiles
Publications générales
- Buesing C, Fisch G, O'Donnell M, Shahidi I, Thomas L, Mummidisetty CK, Williams KJ, Takahashi H, Rymer WZ, Jayaraman A. Effects of a wearable exoskeleton stride management assist system (SMA(R)) on spatiotemporal gait characteristics in individuals after stroke: a randomized controlled trial. J Neuroeng Rehabil. 2015 Aug 20;12:69. doi: 10.1186/s12984-015-0062-0.
- Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: Final Data for 2016. Natl Vital Stat Rep. 2018 Jul;67(5):1-76.
- He Y, Eguren D, Luu TP, Contreras-Vidal JL. Risk management and regulations for lower limb medical exoskeletons: a review. Med Devices (Auckl). 2017 May 9;10:89-107. doi: 10.2147/MDER.S107134. eCollection 2017.
- Lee SH, Lee HJ, Chang WH, Choi BO, Lee J, Kim J, Ryu GH, Kim YH. Gait performance and foot pressure distribution during wearable robot-assisted gait in elderly adults. J Neuroeng Rehabil. 2017 Nov 28;14(1):123. doi: 10.1186/s12984-017-0333-z.
- Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury: a systematic review. Arch Phys Med Rehabil. 2013 Nov;94(11):2297-308. doi: 10.1016/j.apmr.2013.06.023. Epub 2013 Jul 9.
Liens utiles
- <p>Mapping Connections. An Understanding of Neurological Conditions in Canada. The National Population Health Study of Neurological Conditions.: Neurological Health Charities Canada. Government of Canada. Canadian Institutes of Health Research.</p>
- <p>Canada S. Canada at a Glance 2018. Population</p>
- <p>Medical Devices; Physical Medicine Devices; Classification of the Powered Exoskeleton A Rule by the Food and Drug Administration on 02/24/2015</p>
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Manifestations neurologiques
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- AVC ischémique
- AVC hémorragique
- Accident vasculaire cérébral
- Parésie
Autres numéros d'identification d'étude
- KEOG-SE-002
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .